Esperion Therapeutics, Inc. — Earnings Quality Grade F
ESPR · Healthcare
Major red flags
Screening Summary
管理层信号
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO surged by 39 days (88 → 127)
Small-cap context: DSO swings on a small revenue base are more often quarterly customer-mix effects than red flags.
AR growth 74.9% exceeds revenue growth 21.3%
Revenue 21.3%, CFFO 44.6%. Cash follows revenue
Expense Quality
Inventory 11.3% vs COGS 88.4%. Normal
Insufficient data
SG&A/Gross Profit = 60.5%. Normal
Gross margin swung -11.4pp (79.4% → 67.9%)
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
Small-cap context: Small-cap CFFO/NI often diverges from working-capital swings, not necessarily manipulation.
FCF is negative ($-0.0B)
Accruals ratio = -2.1%. Low accruals
Cash $0.2B covers 67% of debt $0.3B
Balance Sheet Health
No goodwill. Clean balance sheet
Interest coverage = 0.7x (<2x). Financial stress
Insufficient data
No write-off data
Acquisition Risk
FCF after acquisitions positive
No goodwill
Manipulation Score
M-Score = -1.99 (grey zone)
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25